Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.
BACKGROUND
There is a move towards treatment of Parkinson's disease (PD) patients in specialized units, however, data on the outcome and on daily antiparkinsonian drug costs are rare.


OBJECTIVE
The objective of this study was to elucidate relationships between costs of drug treatment and efficacy of drug titration in a PD clinic.


METHODS
We calculated costs of drug therapy and scored severity of PD of 63 consecutively referred in-patients initially and at the end of their hospital stay under standardized conditions.


RESULTS
Titration of antiparkinsonian drugs significantly induced a decrease of PD symptoms and an increase of daily drug costs. There were significant correlations between the degree of (i) improvement of the UPDRS score, (ii) increase of dopaminergic agents and (iii) change of corresponding daily antiparkinsonian drug costs.


CONCLUSIONS
Our results demonstrate the effectiveness of treatment in PD clinics, which results in increased daily antiparkinsonian drug costs due to elevated dopaminergic substitution.
Müller
Thomas
T
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de
Voss
Birgit
B
Hellwig
Kerstin
K
Przuntek
Horst
H
D000368:Aged; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics* / Q000503:physiopathology; D011597:Psychomotor Performance